ZA200610052B - Treatment with irinotecan (CPT-11) and an EGFR-inhibitor - Google Patents

Treatment with irinotecan (CPT-11) and an EGFR-inhibitor

Info

Publication number
ZA200610052B
ZA200610052B ZA200610052A ZA200610052A ZA200610052B ZA 200610052 B ZA200610052 B ZA 200610052B ZA 200610052 A ZA200610052 A ZA 200610052A ZA 200610052 A ZA200610052 A ZA 200610052A ZA 200610052 B ZA200610052 B ZA 200610052B
Authority
ZA
South Africa
Prior art keywords
cpt
irinotecan
egfr
inhibitor
treatment
Prior art date
Application number
ZA200610052A
Other languages
English (en)
Inventor
Chen Jianping
Kolinsky Kenneth
Higgins Brian
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34968128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200610052(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200610052B publication Critical patent/ZA200610052B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200610052A 2004-06-03 2006-11-30 Treatment with irinotecan (CPT-11) and an EGFR-inhibitor ZA200610052B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57650304P 2004-06-03 2004-06-03

Publications (1)

Publication Number Publication Date
ZA200610052B true ZA200610052B (en) 2008-08-27

Family

ID=34968128

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200610052A ZA200610052B (en) 2004-06-03 2006-11-30 Treatment with irinotecan (CPT-11) and an EGFR-inhibitor

Country Status (16)

Country Link
US (1) US20050272737A1 (xx)
EP (1) EP1761264A1 (xx)
JP (1) JP2008501651A (xx)
CN (1) CN1960730A (xx)
AR (1) AR049136A1 (xx)
AU (1) AU2005249201A1 (xx)
BR (1) BRPI0511800A (xx)
CA (1) CA2566971A1 (xx)
IL (1) IL179373A0 (xx)
MX (1) MXPA06013999A (xx)
NO (1) NO20066080L (xx)
NZ (1) NZ551355A (xx)
RU (1) RU2006146625A (xx)
TW (1) TW200603804A (xx)
WO (1) WO2005117877A1 (xx)
ZA (1) ZA200610052B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1982718A4 (en) * 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd ANTICANCER PHARMACEUTICAL COMPOSITION
CA2683109A1 (en) * 2006-10-11 2008-04-17 Fusion Antibodies Limited Combination therapy
WO2008076949A2 (en) * 2006-12-15 2008-06-26 Concert Pharmaceuticals Inc. Quinazoline derivatives and methods of treatment
US20100260674A1 (en) * 2006-12-15 2010-10-14 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
WO2009121042A1 (en) * 2008-03-28 2009-10-01 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
EP2344161B1 (en) * 2008-10-16 2018-12-19 Celator Pharmaceuticals, Inc. Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9980953B2 (en) * 2016-09-26 2018-05-29 Chong Kun Dang Pharmaceutical Corp. Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
SK16522001A3 (sk) * 1999-05-14 2002-10-08 Imclone Systems Incorporated Liečivo na inhibíciu rastu refraktérnych nádorov
AU2002239486A1 (en) * 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
BR0116575A (pt) * 2001-01-09 2004-01-06 Merck Patent Gmbh Terapia combinada que usa inibidores de tirosina cinase receptora e inibidores de angiogênese
PA8578001A1 (es) * 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
US20050250709A1 (en) * 2003-12-19 2005-11-10 Bionaut Pharmaceuticals Anti-neoplastic agents, combination therapies and related methods
JP2008501650A (ja) * 2004-06-03 2008-01-24 エフ．ホフマン−ラ　ロシュ　アーゲー オキサリプラチンおよびｅｇｆｒ阻害剤を用いた処置
JP2008501652A (ja) * 2004-06-03 2008-01-24 エフ．ホフマン−ラ　ロシュ　アーゲー ゲムシタビン及びｅｇｆｒインヒビターによる治療
BRPI0510657A (pt) * 2004-06-03 2007-12-04 Hoffmann La Roche tratamento com cisplatina e com um inibidor de egfr
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
US20060084675A1 (en) * 2004-10-18 2006-04-20 Thomas Efferth Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor
US20060084691A1 (en) * 2004-10-18 2006-04-20 Bilal Piperdi Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
US20060134064A1 (en) * 2004-12-20 2006-06-22 David Goldstein Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor
EP1996193A2 (en) * 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors

Also Published As

Publication number Publication date
IL179373A0 (en) 2007-03-08
NO20066080L (no) 2007-01-03
EP1761264A1 (en) 2007-03-14
TW200603804A (en) 2006-02-01
BRPI0511800A (pt) 2008-01-15
WO2005117877A1 (en) 2005-12-15
NZ551355A (en) 2009-09-25
CN1960730A (zh) 2007-05-09
US20050272737A1 (en) 2005-12-08
MXPA06013999A (es) 2007-02-08
CA2566971A1 (en) 2005-12-15
JP2008501651A (ja) 2008-01-24
RU2006146625A (ru) 2008-07-20
AU2005249201A1 (en) 2005-12-15
AR049136A1 (es) 2006-06-28

Similar Documents

Publication Publication Date Title
ZA200610052B (en) Treatment with irinotecan (CPT-11) and an EGFR-inhibitor
IL179525A0 (en) Treatment with gemcitabine and an egfr-inhibitor
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
IL179533A0 (en) Treatment with cisplatin and an egfr-inhibitor
ZA200705402B (en) Respiratory devices and methods of use
EP1755733A4 (en) METHOD AND DEVICES FOR THERMAL TREATMENT
EP1727498A4 (en) DEVICES AND METHODS FOR ENDOVASCULAR TREATMENT
EP1804831A4 (en) VACCINES BASED ON LLO AND LISTERIA
EP1945284A4 (en) SPRAYING DEVICES, COMPONENTS OF SPRAYING DEVICES AND METHOD FOR DEVELOPING COMPONENTS AND SPRAYING DEVICES
EP1817073A4 (en) IMPROVED DEVICES AND METHODS OF ENERGY DELIVERY
HK1110811A1 (en) Medicine injection devices and methods
GB2435590B (en) An interleaver and associated methods
EP1733749A4 (en) SYRINGE WITH COUPLING, SYRINGE FITTING AND SYRINGE
EP1797186A4 (en) EXPRESSION SYSTEM, ITS COMPONENTS AND USE METHOD
IL177845A0 (en) Combination therapy with glatiramer acetate and riluzole
GB0406088D0 (en) Infusion apparatus and methods
ZA200704136B (en) Particle-size reduction apparatus, and use thereof
IL178492A0 (en) Cancer treatment using viruses and camptothecins
GB0406085D0 (en) Infusion apparatus and methods
EP1737565A4 (en) COS CLAUS CONFIGURATIONS AND METHODS
GB2433897B (en) Gaming systems and methods
EP1840948A4 (en) FINE TREATMENT AGENT AND FINE TREATMENT METHOD USING THE SAME
ZA200610050B (en) Treatment with oxaliplatin and an EGFR-inhibitor
HK1113686A1 (en) Biotinylated hexadecasaccharides, preparation and use thereof
GB0407382D0 (en) Therapeutic methods and means